Search results
Showing 1 to 15 of 8149 results
Details, meeting dates and minutes of the independent technology appraisal committees
Our board meetings are open to the public. You can download the agenda, papers and minutes for each meeting.
Agenda and papers of the NICE public board meeting on 20 March 2024
Early value assessment (EVA) guidance on the ProKnow cloud-based system for radiotherapy data storage, communication and management....
NICE research projects and partners.
Data on the recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
Data on the cancer recommendations made by our technology appraisal programme. Includes information on the number of positive recommendations we've made.
This guideline covers managing COVID-19 in babies, children, young people and adults in community and hospital settings. It includes recommendations on communication, assessment, therapeutics for COVID-19, non-invasive respiratory support, preventing and managing acute complications, and identifying and managing co-infections.
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)
Evidence-based recommendations on fluocinolone acetonide intravitreal implant (Iluvien) for visual impairment caused by chronic diabetic macular oedema that has not responded well enough to available treatments in adults.
Dupilumab for treating moderate to severe prurigo nodularis (TA955)
Evidence-based recommendations on dupilumab (Dupixent) for treating moderate to severe prurigo nodularis in adults when systemic treatment is suitable.
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
Resources to help organisations who want to help develop NICE guidance
Take part in the production of medical technologies guidance.
Advises NICE on the formulation of its guidance on the safety and efficacy of interventional procedures.
Our health inequalities guidance supports strategies that improve population health as a whole, while offering particular benefit to the most disadvantaged